Julia Owens: A Deep Dive Into Stroke Care and Basking Bio’s Innovative Programs
Julia Owens, Chief Executive Officer at Basking Biosciences Inc, reposted from Basking Biosciences, Inc. on LinkedIn:
”I have long admired Josh Schimmer‘s biotech insights and wit, so I was thrilled when he wanted to learn more about our work at Basking Bio.
I hope you will listen to this webinar where Josh and Alexa dig into the background of stroke care and our innovative programs with their usual probing questions.”
Quoting Basking Biosciences, Inc.‘s post:
”We had the privilege of joining Josh Schimmer and Alexa Deemer Conzola at Cantor Fitzgerald for a deep dive into acute ischemic stroke and the science behind our lead program, BB-031.
In the recording below, our CEO, Julia Owens, and Co-founder and Chief Scientific Officer, Dr. Shahid Nimjee, walk through the stroke treatment landscape, why targeting von Willebrand Factor represents a fundamentally different approach, and where BB-031 stands in its clinical development.
Thank you, Josh and the Cantor team, for the opportunity to share our story with your audience.
Stay updated with Hemostasis Today.
-
Jun 18, 2026, 23:52WFH Regional Conference on Advancing Bleeding Disorders Care
-
Jun 18, 2026, 19:53Astha Thakkar: What Is the Most Important Test for a Bleeding Disorder?
-
Jun 18, 2026, 19:53Shehab Mohamed: Real-World Evidence on Maternal and Neonatal Outcomes in ITP
-
Jun 18, 2026, 19:51Mawadda Chukr: What 10 Randomized Trials Reveal About Novel ITP Therapies
-
Jun 18, 2026, 19:49Ana Rita Santos: Cost-Effectiveness of Chatbot-Supported Remote Monitoring for Anticoagulation Management
-
Jun 18, 2026, 19:46Angela Fan: Highlighting the Significant Burden Faced by Patients Living With PV
-
Jun 18, 2026, 15:29Santagata Davide: Timely Removal of Retrievable IVC Filters May Reduce VTE Recurrence and Mortality
-
Jun 18, 2026, 15:13Youssef Afifi: The Thrombocytosis–Bleeding Paradox
-
Jun 18, 2026, 15:06Nihala Sharin E A: The Vital Role of Hematology in the Medical Laboratory